NCT04003246View on ClinicalTrials.gov

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

June 15, 2022

Study Completion Date

November 5, 2024

Conditions
Non Small Cell Lung CancerLung Cancer Stage III
Interventions
RADIATION

Thoracic RT and Durvalumab

1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation

DRUG

Consolidative Durvalumab

1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year

Trial Locations (1)

75390

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER